MedTrace Logo

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

NCT04492618 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-02-08

Study results available
· View outcomes & findings →

Summary

This research study is evaluating the safety and efficacy of a topical drug treatment "Ruxolitinib" in treating Necrobiosis Lipoidica (NL).

Conditions

  • Necrobiosis Lipoidica

Interventions

DRUG

Ruxolitinib

Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica

Sponsors & Collaborators

  • Aaron R. Mangold

    lead OTHER

Principal Investigators

  • Aaron R Mangold · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2022-03-16
Completion
2022-03-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04492618 on ClinicalTrials.gov